AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05114135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteo3 ZP Putty
Description: Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.
Study NCT06069479 — intervention group
Intervention type: PROCEDURE
Intervention: craniofacial surgery
Description: Surgical treatment, either stripcraniectomy or fronto-orbital advancement
Study NCT05602987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enema
Description: receiving enema at the night before anal surgery
Study NCT05602987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no enema
Description: no enema before anal surgery
Study NCT05188092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound guided deresuscitation
Description: With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~1. LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~2. LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~3. LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours.
Study NCT04964128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)
Description: The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
Study NCT05628909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV with SO tamponade
Description: Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
Study NCT05628909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV with fovea-sparing ILMP and gas tamponade
Description: Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
Study NCT05628909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV with gas tamponade
Description: Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
Study NCT05174169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX 6 month
Description: Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
Study NCT04889872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
Description: Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
Study NCT05302648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Derived anti-BCMA CAR-T Injection
Description: Autologous genetically modified anti-BCMA CAR transduced T cells
Study NCT06111781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relugolix 120 MG [Orgovyx]
Description: ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
Study NCT06111781 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT standard of care radiotherapy treatment
Description: SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
Study NCT05864911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Gastric Bypass Stent System
Description: The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
Study NCT05188209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study NCT05766930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study NCT05441527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI Paste, then, Biotene Dry Mouth Gel
Description: 1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
Study NCT05441527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Dry Mouth Gel, then, MI Paste
Description: 1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
Study NCT05190198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Description: * Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~* One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~* One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~* Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~* In standing position, moving the weight left and right maximally.~* In standing position, moving the weight forward and backward maximally.~* In standing position, moving both heels of feet up and down.~* In standing position, bending and stretching both knees by squatting as much as possible.
Study NCT05190198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: (Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min).
Study NCT04928677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codrituzumab
Description: For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
Study NCT05568784 — intervention group
Intervention type: OTHER
Intervention: Straight Leg Raise exercise
Description: Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
Study NCT06275282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramuscular electrodes
Description: Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
Study NCT06341738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video education about HPV and HPV vaccine
Description: video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.
Study NCT06341738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic reminder messages
Description: Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
Study NCT06264206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Killer-cell immunoglobulin-like receptors (KIRs) testing
Description: patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.
Study NCT05752110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
Study NCT05752110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.09% Saline (0.05ml/kg) intravenously administered
Study NCT06456333 — intervention group
Intervention type: DEVICE
Intervention: High-density surface electromyography
Description: Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)
Study NCT06341738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Information Service
Description: this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
Study NCT06418503 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance Training
Description: Participants will complete 16 sessions of balance training (30 min. each) over one month.
Study NCT06418503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG-Biofeedback Training
Description: Participants will complete 16 sessions of EMG-biofeedback balance training (30 min. each) over one month.
Study NCT05112380 — intervention group
Intervention type: OTHER
Intervention: Performing Xco endurance test
Description: The subjects will perform the test two times, with 7-10 days between the two sessions
Study NCT04662801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will receive twelve weeks of BWL treatment.
Study NCT04662801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Responder: BWL continued
Description: Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
Study NCT04662801 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Early Non-responder: BWL continued with medication added
Description: Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
Study NCT05263895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-07321332/ritonavir
Description: PF-07321332 ritonavir will be administered as single dose orally
Study NCT04978818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaxelis
Description: Eligible infants will be block randomized to one of two study arms.
Study NCT04978818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB
Description: Eligible infants will be block randomized to one of two study arms.
Study NCT05263895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332 ritonavir will be administered as single oral dose orally.
Study NCT05263895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: PF-07321332 will be administered as single oral dose orally.
Study NCT05904457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.
Study NCT05904457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.
Study NCT05403879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation of greater tuberosity fractures
Description: deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
Study NCT05133687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
Study NCT05133687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
Study NCT06429501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Epinephrine
Description: injection
Study NCT06429501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: injection
Study NCT04075487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-module for patient education and planning
Description: Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
Study NCT05797493 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: Upfront chemo-immunotherapy
Study NCT04840914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3461767
Description: Administered SC.
Study NCT04840914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT06092866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital triage
Description: A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
Study NCT06180707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin gel
Description: 10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
Study NCT06180707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel with 5% potassium nitrate and 2% sodium fluoride
Description: gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
Study NCT06180707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
Study NCT04794023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corneal Ablation
Description: Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
Study NCT05367323 — intervention group
Intervention type: DEVICE
Intervention: Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)
Description: Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively
Study NCT06092866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital triage
Description: A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
Study NCT06256042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint
Description: a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
Study NCT06256042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis
Description: The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
Study NCT05040581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-Day CBT-Based Workshop for Preventing PPD
Description: The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
Study NCT05341700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact Load Exercises
Description: Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
Study NCT05341700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Impact Load Exercises
Description: Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
Study NCT05376839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedirogant
Description: Capsule, Oral
Study NCT06136611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
Study NCT04859374 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfullness
Description: Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
Study NCT04859374 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: treatment as usual (TAU) (pharmacological)
Description: Any pharmacological therapy used for managing chronic pain or chronic migraine
Study NCT06186986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
Study NCT06500403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: liver and stiffness measurement
Description: liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
Study NCT05537935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Naltrexone
Description: Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which is seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
Study NCT05636306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NoNO-42
Description: A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
Study NCT05636306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
Study NCT05614141 — intervention group
Intervention type: DEVICE
Intervention: Lokomat Augmented Performance Feedback
Description: All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
Study NCT05614141 — intervention group
Intervention type: OTHER
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
Study NCT05536544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IBDMED
Description: The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
Study NCT05536544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Dietary counseling according to the local dietary guidelines for patients with IBD